Home Health Pharma Research, PDRN injection SCIE paper reveals “Chronic rotator cuff tendinopathy treatment effect”

Pharma Research, PDRN injection SCIE paper reveals “Chronic rotator cuff tendinopathy treatment effect”

by news dir
Pharma Research’s trial results for PDRN prolo-treated patients

Pharma Research (CEO Ki-seok Kang · Shin-kyu Kim) published the ‘PAIN RESEARCH & MANAGEMENT’ paper published in the SCIE-level journal in 2018 regarding the fact that PDRN injection is also effective in treating chronic rotator cuff tendinopathy. said to have been disclosed.

The title of the paper published at the time was “PDRN Ultrasound-Guided Prolotherapy with Polydeoxyribonucleotide for Painful Rotator Cuff Tendinopathy”. In the case of chronic RCT (rotator cuff tendinopathy) patients, which are difficult to treat with conservative therapy, the main content of the paper is that PDRN treatment is effective for at least 3 months.

The final study analyzed 32 patients with refractory rotator cuff disease, and the average number of injections was 3.9. Of these, 11 patients received injections 3 times, 12 patients 4 times, and 5 injections 5 times. As a result, patients who received PDRN treatment had less pain after 1 month (1.8) and 3 months (1.7) than 1 week (5.3) treatment on the ‘pain visual analog scale’ (VAS), which is the ‘pain visual analog score’.

In the ‘single assessment numeric evaluation (SANE)’, the evaluation was more improved at 1 month (80.3) and 3 months (85.7) than at 1 week (46.6) after treatment, and the shoulder pain and disability index SPDI (shoulder) In the evaluation of the pain and disability index, there was a marked improvement in pain reduction after 1 month (16.9) and 3 months (12.6) treatment compared to 1 week (45.8).

In addition, complications such as infection, allergy, and pain after injection did not occur during the treatment process. The researchers reported that the treatment of rotator cuff tendinopathy does not have side effects such as ‘local inflammation’, ‘necrosis’, and ‘tendon ligament weakness or destruction’ that can occur with repeated steroid injections.

When PDRN treatment progresses, there are no drug restrictions because PDRN promotes proliferation without an inflammatory phase, and the treatment period is shorter than when using glucose. Glucose prolotherapy can usually take at least 9 to 20 weeks, whereas PDRN treatment can take 3 to 5 weeks.

According to the report, “Treatment with PDRN is an effective treatment for refractory ‘chronic rotator cuff tendinopathy’ because it reduces pain, improves function and reduces disability in daily life.” It reduces the initial inflammatory factors, including tumor necrosis factor-alpha, interleukin-1 and interleukin-6, and later reduces the pro-inflammatory factor HMGB-1.”

Related Articles

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.